If you've ever wondered why drugmakers run Phase I-II or II B clinical trials, how drugmakers like AbbVie (NYSE: ABBV) plan on keeping generic drugmakers at bay after their patents expire, or why pharmacy retailers like Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS) aren't making more money off aging baby boomers, you're not alone.Listeners to The Motley Fool's Industry Focus: Healthcare podcast asked those exact questions, and in today's show, analyst Kristine Harjes and contributor Todd Campbell answer them.